Abeona Therapeutics announces publication in The Lancet of Phase 3 VITAL study

Abeona Therapeutics (ABEO) announced that The Lancet has published results from the pivotal Phase 3 VIITAL study evaluating the efficacy and safety of ZEVASKYN gene-modified cellular sheets, also known as pz-cel, for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. This article, titled, “Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa Wounds: A Two-Centre, Randomised, Open-Label, Intrapatient-Controlled Phase 3 Trial,” representing the primary publication of the full VIITAL study data, is now available online and will be published in a future print issue of The Lancet. ZEVASKYN demonstrated significant wound healing and pain reduction after a single treatment with a favorable safety profile in large chronic RDEB wounds